Major Depressive Disorder

134
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
22
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
1
30
7
52
36
Early DiscoveryClinical DevelopmentMarket

On Market (22)

Approved therapies currently available

U
APREPITANTApproved
aprepitant
Unknown Company
Substance P/Neurokinin-1 Receptor Antagonist [EPC]oral2017
Eli Lilly and Company
CYMBALTAApproved
duloxetine hydrochloride
Eli Lilly and Company
oral2004
U
DULOXETINE HYDROCHLORIDEApproved
duloxetine
Unknown Company
oral2017
M&
EMENDApproved
aprepitant
Merck & Co.
Substance P/Neurokinin-1 Receptor Antagonist [EPC]oral2003
U
ESCITALOPRAM OXALATEApproved
escitalopram
Unknown Company
oral2016
VP
HETLIOZApproved
tasimelteon
Vanda Pharmaceuticals
Melatonin Receptor Agonist [EPC]oral2014
VP
HETLIOZ LQApproved
tasimelteon
Vanda Pharmaceuticals
Melatonin Receptor Agonist [EPC]oral2020
Corcept Therapeutics
KORLYMApproved
mifepristone
Corcept Therapeutics
Progestin Antagonist [EPC]oral2012
U
MIFEPREXApproved
mifepristone
Unknown Company
oral2000
Eli Lilly and Company
PROZACApproved
fluoxetine hydrochloride
Eli Lilly and Company
oral1987
J&
RISPERDALApproved
risperidone
Johnson & Johnson
Atypical Antipsychotic [EPC]oral2003
J&
RISPERDAL CONSTAApproved
risperidone
Johnson & Johnson
intramuscular2003
U
RISPERIDONEApproved
risperidone
Unknown Company
Atypical Antipsychotic [EPC]oral2009
U
RISVANApproved
risperidone
Unknown Company
intramuscular2024
U
SEROQUELApproved
quetiapine
Unknown Company
oral1997
U
SEROQUEL XRApproved
quetiapine
Unknown Company
oral2007
Takeda
TRINTELLIXApproved
vortioxetine
Takeda
oral2013
U
VORTIOXETINEApproved
vortioxetine
Unknown Company
oral
U
VORTIOXETINE HYDROBROMIDEApproved
vortioxetine
Unknown Company
AbbVie
VRAYLARApproved
cariprazine
AbbVie
Atypical Antipsychotic [EPC]oral2015
U
ZYPREXAApproved
olanzapine
Unknown Company
Atypical Antipsychotic [EPC]oral1996
U
ZYPREXA ZYDISApproved
olanzapine
Unknown Company
Atypical Antipsychotic [EPC]oral2000

Competitive Landscape

39 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
13 programs
3
1
4
2
DuloxetinePhase 41 trial
DuloxetinePhase 41 trial
DuloxetinePhase 31 trial
LY2216684Phase 31 trial
OlanzapinePhase 31 trial
+8 more programs
Active Trials
NCT00071708Approved For Marketing
NCT00208897Completed80Est. Nov 2007
NCT00485420Completed404Est. Dec 2009
+10 more trials
Takeda
TakedaTOKYO, Japan
9 programs
1
6
1
VortioxetinePhase 41 trial
EscitalopramPhase 31 trial
Lu AA21004Phase 31 trial
SPD489Phase 31 trial
TRINTELLIX(Vortioxetine)Phase 35 trials
+4 more programs
Active Trials
NCT04891224Completed89Est. Jan 2023
NCT03242213Completed40Est. Sep 2019
NCT01435759Completed1,197Est. Jan 2014
+11 more trials
Alto Neuroscience
Alto NeuroscienceMOUNTAIN VIEW, CA
9 programs
7
2
DuloxetinePhase 41 trial
SertralinePhase 41 trial
ALTO-100Phase 21 trial
ALTO-100 PO TabletPhase 21 trial
ALTO-100 PO tabletPhase 21 trial
+4 more programs
Active Trials
NCT05712187CompletedEst. Oct 2024
NCT05419869CompletedEst. Jan 2023
NCT05117632CompletedEst. Dec 2022
+6 more trials
BrainsWay
BrainsWayJerusalem, Israel
8 programs
1
2
1
Brainsway DTMS with intermittent Theta Burst StimulationPhase 41 trial
Deep Transcranial Magnetic StimulationPhase 2/31 trial
Deep Transcranial Magnetic StimulationPhase 2/31 trial
H-coil dTMSPhase 21 trial
Brainsway Deep TMS SystemN/A1 trial
+3 more programs
Active Trials
NCT06357832Active Not RecruitingEst. Apr 2026
NCT00927173CompletedEst. Jun 2012
NCT01860157CompletedEst. Dec 2016
+5 more trials
Pfizer
PfizerNEW YORK, NY
8 programs
4
1
Effexor XRPhase 41 trial
DVS SRPhase 31 trial
DVS-233 SRPhase 35 trials
Desvenlafaxine Succinate Sustained-Release 10mgPhase 31 trial
sertralinePhase 31 trial
+3 more programs
Active Trials
NCT05902494Completed389Est. Jun 2025
NCT00770289Completed851Est. Dec 2009
NCT04446039Completed370,212Est. Nov 2022
+13 more trials
Alliance Pharmaceuticals
7 programs
1
1
1
acamprosatePhase 42 trials
D-cycloserinePhase 22 trials
MemantinePhase 11 trial
CytomelN/A1 trial
Exploring a Potential Blood Test to Diagnose Major Depressive DisorderN/A
+2 more programs
Active Trials
NCT00562367Completed30Est. Sep 2004
NCT03749629Completed201Est. Mar 2022
NCT00245557Completed43Est. Aug 2008
+5 more trials
Axsome Therapeutics
Axsome TherapeuticsNY - New York
5 programs
2
2
1
AXS-05Phase 41 trial
AXS-05Phase 31 trial
Solriamfetol 300 mgPhase 31 trial
AXS-05Phase 21 trial
AXS-05Phase 21 trial
Active Trials
NCT03595579Completed97Est. Jan 2019
NCT04971291Unknown312Est. Jul 2021
NCT04039022Completed876Est. Oct 2020
+2 more trials
Corcept Therapeutics
1
4
1
MifepristonePhase 31 trial
MifepristonePhase 31 trial
MifepristonePhase 31 trial
mifepristonePhase 31 trial
MifepristonePhase 21 trial
Active Trials
NCT05217758Completed158Est. Nov 2024
NCT00128505Completed104Est. Nov 2006
NCT00146523Completed247Est. Jul 2006
+2 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
4 programs
1
3
DuloxetinePhase 41 trial
Duloxetine hydrochloridePhase 41 trial
duloxetine hydrochloridePhase 41 trial
Amisulpride PillPhase 11 trial
Active Trials
NCT05347199Completed127Est. Sep 2023
NCT00985504Completed483Est. Dec 2010
NCT00422162Completed339Est. Aug 2008
+1 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
1
CariprazinePhase 31 trial
IcalcaprantPhase 21 trial
Active Trials
NCT07276997Recruiting195Est. Sep 2027
NCT03738215Completed759Est. Sep 2021
J&
1
1
1
RISPERDAL(risperidone)Phase 35 trials
R228060Phase 21 trial
Active Trials
NCT00073203Completed488Est. May 2004
NCT00253149Completed158Est. Apr 1999
+3 more trials
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
1
tasimelteonPhase 2/31 trial
Active Trials
NCT01428661Completed507Est. May 2013
M&
Merck & Co.RAHWAY, NJ
1 program
1
1
EMEND(aprepitant)Phase 35 trials
Active Trials
NCT00429754Withdrawn0Est. Sep 2008
NCT04054193Completed103Est. Feb 2021
NCT02445872Unknown80Est. May 2016
+2 more trials
Verona Pharma
Verona PharmaUK - London
1 program
1
VortioxetinePhase 41 trial
Active Trials
NCT03779789Completed362Est. Feb 2023
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
bupropion hydrobromidePhase 41 trial
Active Trials
NCT02129751Not Yet RecruitingEst. Dec 2029
Neuronetics
NeuroneticsMALVERN, PA
8 programs
1
Repetitive Transcranial Magnetic StimulationPhase 31 trial
Active NeuroStar® Transcranial Magnetic StimulationN/A1 trial
NeuroStar TMSN/A1 trial
NeuroStar TMS Therapy System: Utilization and OutcomesN/A1 trial
NeuroStar TMS Therapy® SystemN/A1 trial
+3 more programs
Active Trials
NCT02586688Completed112Est. Dec 2018
NCT01415154Completed67Est. Jul 2014
NCT01114477Completed307Est. Sep 2012
+5 more trials
Alkermes
8 programs
1
1
6
ALKS 5461Phase 31 trial
ALKS 5461Phase 31 trial
ALKS 5461Phase 31 trial
ALKS 5461Phase 31 trial
ALKS 5461Phase 31 trial
+3 more programs
Active Trials
NCT01381107CompletedEst. Jul 2011
NCT01500200CompletedEst. Mar 2013
NCT02085135CompletedEst. Sep 2014
+5 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
6 programs
4
QuetiapinePhase 35 trials
Quetiapine fumaratePhase 31 trial
TC-5214Phase 31 trial
TC-5214Phase 34 trials
Antidepressant Incomplete Response DepressionN/A1 trial
+1 more programs
Active Trials
NCT00782964Completed364Est. Nov 2009
NCT01446692Completed2,260Est. Jan 2012
NCT01795326Completed800Est. Sep 2013
+10 more trials
Relmada Therapeutics
3
REL-1017Phase 31 trial
REL-1017Phase 31 trial
REL-1017Phase 31 trial
REL-1017N/A1 trial
Active Trials
NCT06009003Temporarily Not Available
NCT04688164CompletedEst. Nov 2022
NCT04855760CompletedEst. Jul 2023
+1 more trials
Xenon Pharmaceuticals
1
3
AzetukalnerPhase 31 trial
AzetukalnerPhase 31 trial
AzetukalnerPhase 31 trial
XEN1101 10 mgPhase 21 trial
Active Trials
NCT05376150Completed168Est. Oct 2023
NCT06775379Recruiting450Est. Oct 2026
NCT07076407Recruiting450Est. Jul 2027
+1 more trials
Novartis
NovartisBASEL, Switzerland
3 programs
1
2
AgomelatinePhase 31 trial
AgomelatinePhase 32 trials
MIJ821Phase 11 trial
Active Trials
NCT05666687Completed10Est. Nov 2023
NCT00463242Completed501
NCT01156415Terminated837Est. Oct 2011
+1 more trials
Gedeon Richter
Gedeon RichterHungary - Budapest
3 programs
1
2
CariprazinePhase 31 trial
CariprazinePhase 31 trial
Antidepressant + placeboPhase 21 trial
Active Trials
NCT00854100Completed231Est. Dec 2010
NCT01715805Completed1,022Est. Jun 2016
NCT01838876Completed442Est. Jul 2015
Sanofi
SanofiPARIS, France
3 programs
3
SR58611APhase 31 trial
SR58611APhase 35 trials
amibegronPhase 33 trials
Active Trials
NCT00432614Completed510Est. Feb 2008
NCT00535340Terminated55Est. Aug 2007
NCT00397098Terminated257Est. Sep 2007
+6 more trials
Compass Therapeutics
2 programs
1
1
PsilocybinPhase 31 trial
PsilocybinPhase 21 trial
Active Trials
NCT05733546Active Not Recruiting102Est. Sep 2025
NCT06247839RecruitingEst. Jun 2026
Compass Pathways
Compass PathwaysUK - Cheshire
2 programs
1
1
PsilocybinPhase 3
PsilocybinPhase 2
Biogen
2 programs
2
SAGE-217Phase 31 trial
SAGE-217Phase 31 trial
Active Trials
NCT03771664Terminated87Est. Jan 2020
NCT04007367Terminated53Est. Jan 2020
Bristol Myers Squibb
1 program
1
Antidepressant + PlaceboPhase 31 trial
Active Trials
NCT00095758Completed1,200Est. Dec 2006
Magnus Medical
Magnus MedicalCA - Burlingame
4 programs
2
Active SAINT StimulationPhase 2/31 trial
Active SAINT StimulationPhase 2/31 trial
MagPro X100 editionN/A1 trial
SAINT® Neuromodulation SystemN/A1 trial
Active Trials
NCT06523439RecruitingEst. Sep 2026
NCT05819021Active Not RecruitingEst. Apr 2027
NCT06462820TerminatedEst. Mar 2025
+1 more trials
Precision BioSciences
3 programs
1
1
PRAX-114Phase 2/31 trial
10 mg PRAX-114Phase 21 trial
Exploring a Potential Blood Test to Diagnose Major Depressive DisorderN/A1 trial
Active Trials
NCT00705185Completed120Est. Jun 2010
NCT04969510Completed110Est. Aug 2022
NCT04832425Completed216Est. May 2022
Praxis Precision Medicines
2 programs
1
1
PRAX-114Phase 2/3
10 mg PRAX-114Phase 2

+9 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Johnson & Johnsonrisperidone
Johnson & Johnsonrisperidone
Merck & Co.aprepitant
Bausch Healthbupropion hydrobromide
Axsome TherapeuticsAXS-05
Johnson & Johnsonrisperidone
Alto NeuroscienceDuloxetine
Alto NeuroscienceSertraline
Merck & Co.aprepitant
TakedaVortioxetine
Verona PharmaVortioxetine
BrainsWayBrainsway DTMS with intermittent Theta Burst Stimulation
Johnson & Johnsonrisperidone
TakedaVortioxetine
TakedaVortioxetine

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,498 patients across 50 trials

A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.

Est. completion: Oct 2004650 patients
Phase 4Completed

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

Est. completion: Aug 200359 patients
Phase 4Completed

Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

Est. completion: Sep 20080
Phase 4Withdrawn
NCT02129751Bausch Healthbupropion hydrobromide

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Start: Jun 2026Est. completion: Dec 2029
Phase 4Not Yet Recruiting

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Start: Dec 2023Est. completion: Mar 2026350 patients
Phase 4Recruiting

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Start: Jul 2021Est. completion: Apr 202493 patients
Phase 4Completed

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Start: Oct 2020Est. completion: May 2023
Phase 4Withdrawn

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Start: Oct 2020Est. completion: May 2023
Phase 4Withdrawn

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Start: Sep 2019Est. completion: Feb 2021103 patients
Phase 4Completed
NCT03580967TakedaVortioxetine

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Start: Jul 2019Est. completion: Jul 20210
Phase 4Withdrawn

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Start: Feb 2019Est. completion: Feb 2023362 patients
Phase 4Completed
NCT04679753BrainsWayBrainsway DTMS with intermittent Theta Burst Stimulation

Brainsway DTMS for Treatment of MDD Using iTBS

Start: Jan 2019Est. completion: Jul 2020
Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Start: Oct 2018Est. completion: Dec 201934 patients
Phase 4Completed
NCT02969876TakedaVortioxetine

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

Start: Aug 2017Est. completion: Aug 20182 patients
Phase 4Terminated
NCT02972632TakedaVortioxetine

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Start: Dec 2016Est. completion: Feb 2018123 patients
Phase 4Completed
NCT02637895TakedaVortioxetine

Vortioxetine for Posttraumatic Stress Disorder

Start: Dec 2016Est. completion: Feb 202041 patients
Phase 4Completed
NCT02749721TakedaVortioxetine

The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Start: Dec 2016Est. completion: Jan 201931 patients
Phase 4Completed
NCT02932904TakedaVortioxetine

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Start: Nov 2016Est. completion: Jun 2017361 patients
Phase 4Completed
NCT03272711TakedaVortioxetine

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

Start: Aug 2016Est. completion: Jan 2019129 patients
Phase 4Completed
NCT02637466TakedaVortioxetine

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

Start: Jul 2016Est. completion: Jul 20190
Phase 4Withdrawn
NCT02357797TakedaVortioxetine

Adjunctive Vortioxetine in Schizophrenia

Start: Feb 2016Est. completion: Jun 202488 patients
Phase 4Unknown
NCT02234362TakedaVortioxetine

Vortioxetine for Menopausal Depression

Start: Jun 2015Est. completion: Sep 201647 patients
Phase 4Completed
NCT02371980TakedaVortioxetine

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Start: Feb 2015Est. completion: Apr 20191,106 patients
Phase 4Completed
NCT02200406PfizerDesvenlafaxine

Desvenlafaxine in Opioid-Dependent Patients

Start: Jul 2014Est. completion: Jan 201718 patients
Phase 4Completed

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

Start: Jan 2013Est. completion: Jun 201517 patients
Phase 4Terminated

A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug

Start: Jul 2012Est. completion: Jun 201313 patients
Phase 4Terminated
NCT01492621PfizerDesvenlafaxine

Effect of Antidepressants on White Matter Structure

Start: Nov 2011Est. completion: Nov 201340 patients
Phase 4Unknown

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Start: Oct 2011Est. completion: Dec 2021146 patients
Phase 4Completed

A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study

Start: Dec 2010Est. completion: Oct 2012131 patients
Phase 4Terminated

Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia

Start: Nov 2010Est. completion: Aug 201175 patients
Phase 4Completed

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Start: Aug 2010Est. completion: Sep 20120
Phase 4Withdrawn
NCT00952653PfizerDesvenlafaxine

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

Start: Jun 2010Est. completion: Aug 201028 patients
Phase 4Completed

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Start: May 2010Est. completion: Dec 2013450 patients
Phase 4Completed

A Study of the Neurobiology of Depression

Start: Jan 2010Est. completion: Mar 201360 patients
Phase 4Completed

Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

Start: Oct 2009Est. completion: Oct 201072 patients
Phase 4Unknown

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Start: Oct 2009Est. completion: Jul 2011244 patients
Phase 4Completed

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Start: Sep 2009Est. completion: Dec 20092 patients
Phase 4Terminated

A Study of Patients With Major Depressive Disorder and Residual Apathy

Start: Sep 2009Est. completion: Dec 2010483 patients
Phase 4Completed

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

Start: Jul 2009Est. completion: Jan 201196 patients
Phase 4Unknown

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Start: Jun 2009Est. completion: Mar 2010163 patients
Phase 4Terminated

Adult Bipolar Mania

Start: Jun 2009Est. completion: Nov 2010356 patients
Phase 4Completed

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Start: Jun 2009Est. completion: Aug 2009139 patients
Phase 4Completed

Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms

Start: May 2009Est. completion: Jul 201039 patients
Phase 4Completed

Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

Start: May 2009Est. completion: Dec 201026 patients
Phase 4Completed

Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder

Start: Apr 2009Est. completion: Oct 20110
Phase 4Withdrawn

Brain Imaging of Quetiapine Response in Anxious Depression

Start: Mar 2009Est. completion: Mar 201220 patients
Phase 4Completed

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Start: Dec 2008Est. completion: Apr 201257 patients
Phase 4Completed

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Start: Nov 2008Est. completion: Feb 201158 patients
Phase 4Completed

Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)

Start: Nov 2008Est. completion: Jul 200996 patients
Phase 4Completed

Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia

Start: Nov 2008Est. completion: Oct 201090 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

52 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 6,498 patients
30 companies competing in this space